{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:05:06Z","timestamp":1790885106053,"version":"4.1.0"},"reference-count":160,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T00:00:00Z","timestamp":1278460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Neuroscience &amp; Therapeutics"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p><jats:bold>Introduction:<\/jats:bold>Central neurochemical systems including the monoamine, opioid, and cannabinoid systems have been promising targets for antiobesity drugs that modify behavioral components of obesity. In addition to modulating eating behavior, centrally acting antiobesity drugs are also likely to alter emotional behavior and cognitive function due to the high expression of receptors for the neurochemical systems targeted by these drugs within the fronto\u2010striatal and limbic circuitry.<jats:bold>Methods:<\/jats:bold>This paper reviewed the neuropsychiatric adverse effects of past and current antiobesity drugs, with a central mechanism of action, linking the adverse effects to their underlying neural substrates and neurochemistry.<jats:bold>Results:<\/jats:bold>Antiobesity drugs were found to have varying neuropsychiatric adverse event profiles. Insomnia was the most common adverse effect with drugs targeting monoamine systems (sibutramine, bupropion and tesofensine). These drugs had some positive effects on mood and anxiety and may have added therapeutic benefits in obese patients with comorbid depression and anxiety symptoms. Sedation and tiredness were the most common adverse effects reported with drugs targeting the m\u2010opioid receptors (i.e., naltrexone) and combination therapies targeting the opioid and monoamine systems (i.e., Contrave\u2122). Cognitive impairments were most frequently associated with the antiepileptic drugs, topiramate and zonisamide, consistent with their sedative properties. Drugs targeting the cannabinoid system (rimonabant and taranabant) were consistently associated with symptoms of anxiety and depression, including reports of suicidal ideation. Similar adverse events have also been noted for the D<jats:sub>1<\/jats:sub>\/D<jats:sub>5<\/jats:sub>antagonist ecopipam.<jats:bold>Conclusion:<\/jats:bold>These findings highlight the need to assess neuropsychiatric adverse events comprehensively using sensitive and validated methods early in the clinical development of candidate antiobesity drugs with a central mechanism of action.<\/jats:p>","DOI":"10.1111\/j.1755-5949.2010.00172.x","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T18:59:56Z","timestamp":1278529196000},"page":"490-505","source":"Crossref","is-referenced-by-count":99,"title":["Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs"],"prefix":"10.1111","volume":"17","author":[{"given":"Pradeep J.","family":"Nathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry V.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"Bullmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,23]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1962.03050370030007"},{"key":"e_1_2_12_3_2","first-page":"999","article-title":"Body weight and psychological distress in NHANES I","volume":"16","author":"Istvan J","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_12_4_2","first-page":"439","volume-title":"Overweight and weight management. The health professional's guide to understanding and practice","author":"Faith MS","year":"1997"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3999(81)90093-3"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3999(78)90018-1"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.2307\/2137335"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.90.2.251"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803122"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcl041"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.117.1.3"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2922597"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.15.1814"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00701.x"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702633"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701312"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702446"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/1028415031000094264"},{"key":"e_1_2_12_19_2","unstructured":"Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee. Transcript of September 28 1995a;345\u2013349."},{"key":"e_1_2_12_20_2","unstructured":"Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee. Transcript of November 16 1995b;1\u2013298."},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(98)00063-3"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1994.tb01480.x"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2004.07.005"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2006.10.003"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.11.1109"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.10.1793-a"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.12.2057-a"},{"key":"e_1_2_12_28_2","first-page":"107","article-title":"Subutramine associated psychosis (case report)","volume":"10","author":"Gazdag G","year":"2008","journal-title":"Neuropsychopharcol Hung"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.19.1.88"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145702003000"},{"key":"e_1_2_12_31_2","first-page":"129","article-title":"Case report: A mixed episode induced by Sibutramine","volume":"13","author":"Eker MC","year":"2003","journal-title":"Klin Psikofarmacol Bul"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7478.1316"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2007.323"},{"key":"e_1_2_12_34_2","volume-title":"Sibutramine, summary of product characteristics","author":"Abbott Laboratories Limited","year":"2000"},{"issue":"1","key":"e_1_2_12_35_2","first-page":"S51","article-title":"Hypothalamic serotonin: Pharmacological, biochemical, and behavioral analyses of its feeding\u2010suppressive action","volume":"11","author":"Leibowitz SF","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026033452249"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.537"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00011-1"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.09.033"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1321"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.461"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2001.71"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.7.1.17"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.86"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.142"},{"key":"e_1_2_12_46_2","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1176\/ajp.156.12.2017-a","article-title":"Bupropion\u2010induced psychosis","volume":"156","author":"Howard WT","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-36393"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.56"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61525-1"},{"key":"e_1_2_12_50_2","first-page":"441","volume-title":"Department of health, education and welfare publication number (NIH) 75\u2010708","author":"Scoville BA","year":"1973"},{"key":"e_1_2_12_51_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.6.1083"},{"key":"e_1_2_12_52_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2006.47.5.614"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(95)00113-R"},{"key":"e_1_2_12_54_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.120.11.1124"},{"key":"e_1_2_12_55_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.156.3.442"},{"key":"e_1_2_12_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199612000-00020"},{"key":"e_1_2_12_57_2","first-page":"44","article-title":"Schizophreniform\u2010like psychotic disorder induced by phentermine: A case report","volume":"61","author":"Lee SH","year":"1998","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_12_58_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.5.711a"},{"key":"e_1_2_12_59_2","first-page":"591","article-title":"Plasma phentermine levels, weight loss and side\u2010effects","volume":"7","author":"Douglas A","year":"1983","journal-title":"Int J Obes"},{"key":"e_1_2_12_60_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2003.02496.x"},{"key":"e_1_2_12_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(99)00239-7"},{"key":"e_1_2_12_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2007.205"},{"key":"e_1_2_12_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(79)90222-4"},{"key":"e_1_2_12_64_2","doi-asserted-by":"publisher","DOI":"10.1017\/S146114570900039X"},{"key":"e_1_2_12_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00928-J"},{"key":"e_1_2_12_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00219-1"},{"key":"e_1_2_12_67_2","first-page":"314","article-title":"Anxiogenic effect of naltrexone in social interaction test in rats","volume":"17","author":"Zhang HT","year":"1996","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"e_1_2_12_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/383535a0"},{"key":"e_1_2_12_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/76061"},{"key":"e_1_2_12_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4530(78)90013-6"},{"key":"e_1_2_12_71_2","volume-title":"Profile of Mood States: Manual","author":"McNair DM","year":"1971"},{"key":"e_1_2_12_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(81)90084-3"},{"key":"e_1_2_12_73_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.9.1081"},{"key":"e_1_2_12_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(87)90202-2"},{"key":"e_1_2_12_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550490290087929"},{"key":"e_1_2_12_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00152-5"},{"key":"e_1_2_12_77_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.71.3.432"},{"key":"e_1_2_12_78_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.8.755"},{"key":"e_1_2_12_79_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2002.tb04550.x"},{"key":"e_1_2_12_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(97)01348-3"},{"key":"e_1_2_12_81_2","first-page":"69","article-title":"Naltrexone for opioid dependence: Evaluation of a manulaized psychosocial protocol to enhance treatment response","volume":"20","author":"Rawson K","year":"2001","journal-title":"Drug Alcoh Rev"},{"key":"e_1_2_12_82_2","first-page":"38","article-title":"Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence","volume":"31","author":"Dean AJ","year":"2006","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_12_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(86)90050-8"},{"key":"e_1_2_12_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(87)90202-2"},{"key":"e_1_2_12_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00161-0"},{"key":"e_1_2_12_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb03931.x"},{"key":"e_1_2_12_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-005-5227-6"},{"key":"e_1_2_12_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830240090013"},{"key":"e_1_2_12_89_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050688"},{"key":"e_1_2_12_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(99)00135-9"},{"key":"e_1_2_12_91_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000666"},{"key":"e_1_2_12_92_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/2.2.175"},{"key":"e_1_2_12_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(82)90102-X"},{"key":"e_1_2_12_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/74.2.188"},{"key":"e_1_2_12_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2008.09.043"},{"key":"e_1_2_12_96_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0022-3565(25)20554-7","article-title":"Naloxone causes a dose\u2010dependent increase in total power and delta wave activity in the EEG of opioid\u2010naive rats","volume":"259","author":"Grasing K","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_12_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.09.007"},{"key":"e_1_2_12_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301440"},{"key":"e_1_2_12_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1457"},{"key":"e_1_2_12_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2136"},{"key":"e_1_2_12_101_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-26573-2_10"},{"key":"e_1_2_12_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03428.x"},{"key":"e_1_2_12_103_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-23-09506.2001"},{"key":"e_1_2_12_104_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.5.1932"},{"key":"e_1_2_12_105_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2002.02192.x"},{"key":"e_1_2_12_106_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.fbp.0000135704.56422.40"},{"key":"e_1_2_12_107_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03293.x"},{"key":"e_1_2_12_108_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-001-0946-5"},{"key":"e_1_2_12_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature00839"},{"key":"e_1_2_12_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500466"},{"key":"e_1_2_12_111_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199701200-00023"},{"key":"e_1_2_12_112_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-200509000-00013"},{"key":"e_1_2_12_113_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.101287"},{"key":"e_1_2_12_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300655"},{"key":"e_1_2_12_115_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300535"},{"key":"e_1_2_12_116_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-1649"},{"key":"e_1_2_12_117_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E499"},{"issue":"1","key":"e_1_2_12_118_2","first-page":"S70","article-title":"SR 141716, a selective CB1 receptor antagonist, reduces hunger, caloric intake and body weight in overweight or obese men","volume":"9","author":"Heshmati HM","year":"2001","journal-title":"Obes Res"},{"key":"e_1_2_12_119_2","first-page":"65","article-title":"141716, SR 141716a","volume":"3","author":"Rimonabant SR","year":"2002","journal-title":"Drugs RD"},{"key":"e_1_2_12_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66374-X"},{"key":"e_1_2_12_121_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn076"},{"key":"e_1_2_12_122_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044537"},{"key":"e_1_2_12_123_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.7.761"},{"key":"e_1_2_12_124_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-44462009000200012"},{"key":"e_1_2_12_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61721-8"},{"key":"e_1_2_12_126_2","unstructured":"Food and Drug Administration Endocrinologic and Metabolic Advisory. June 13 2007. Briefing information NIDA 21\u2013888 ZUMULTI (ribmonabant)\u2010Sinofi\u2010Aventis 2007."},{"key":"e_1_2_12_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60261-5"},{"key":"e_1_2_12_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60263-9"},{"key":"e_1_2_12_129_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0386"},{"key":"e_1_2_12_130_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02454.x"},{"key":"e_1_2_12_131_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.176362"},{"key":"e_1_2_12_132_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2009.00581.x"},{"key":"e_1_2_12_133_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.13.1547"},{"key":"e_1_2_12_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.11.012"},{"key":"e_1_2_12_135_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_2_12_136_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008314467"},{"key":"e_1_2_12_137_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008317591"},{"key":"e_1_2_12_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(00)00452-4"},{"key":"e_1_2_12_139_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.102"},{"key":"e_1_2_12_140_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.4501006.x"},{"key":"e_1_2_12_141_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801873"},{"key":"e_1_2_12_142_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10000"},{"key":"e_1_2_12_143_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.102"},{"key":"e_1_2_12_144_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802783"},{"key":"e_1_2_12_145_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0220-1"},{"key":"e_1_2_12_146_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2001"},{"key":"e_1_2_12_147_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00618.x"},{"key":"e_1_2_12_148_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803548"},{"key":"e_1_2_12_149_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1104"},{"key":"e_1_2_12_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.08.008"},{"key":"e_1_2_12_151_2","first-page":"192","article-title":"Zonisamide: A new antiepileptic drug","volume":"22","author":"Oommen KJ","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_12_152_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.14.1820"},{"key":"e_1_2_12_153_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0108"},{"key":"e_1_2_12_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00078-X"},{"key":"e_1_2_12_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00109-0"},{"key":"e_1_2_12_156_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.461"},{"key":"e_1_2_12_157_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1209"},{"key":"e_1_2_12_158_2","article-title":"Naltrexone + buprobrion combination causes significant weight loss: A 56\u2010week phase 3 study","volume":"69","author":"Wadden T","year":"2009","journal-title":"Ann Meet Am Diabetes Assoc"},{"key":"e_1_2_12_159_2","article-title":"Naltrexone + buprobrion combination causes significant weight loss without worsening psychiatric symptoms","volume":"69","author":"Klein S","year":"2009","journal-title":"Ann Meet Am Diabetes Assoc"},{"key":"e_1_2_12_160_2","first-page":"1117","article-title":"Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity","volume":"10","author":"Padwal R","year":"2009","journal-title":"Curr Opion Inves Drugs"},{"key":"e_1_2_12_161_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1350"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5949.2010.00172.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5949.2010.00172.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T19:13:10Z","timestamp":1740251590000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5949.2010.00172.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,23]]},"references-count":160,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1755-5949.2010.00172.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00172.x","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,23]]}}}